Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma
Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore,...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2020-07-01
|
| Series: | Case Reports in Gastroenterology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/508583 |
| _version_ | 1831523864200347648 |
|---|---|
| author | Tsai-Hung Yen Chung-Hsin Chang Sz-Iuan Shiu |
| author_facet | Tsai-Hung Yen Chung-Hsin Chang Sz-Iuan Shiu |
| author_sort | Tsai-Hung Yen |
| collection | DOAJ |
| description | Tumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden. |
| first_indexed | 2024-12-14T20:39:02Z |
| format | Article |
| id | doaj.art-1f371efce2894b5ab642a7e7b1eaa0a2 |
| institution | Directory Open Access Journal |
| issn | 1662-0631 |
| language | English |
| last_indexed | 2024-12-14T20:39:02Z |
| publishDate | 2020-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Gastroenterology |
| spelling | doaj.art-1f371efce2894b5ab642a7e7b1eaa0a22022-12-21T22:48:19ZengKarger PublishersCase Reports in Gastroenterology1662-06312020-07-0114236737210.1159/000508583508583Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular CarcinomaTsai-Hung YenChung-Hsin ChangSz-Iuan ShiuTumor lysis syndrome (TLS) is a life-threatening emergency that usually develops in rapidly proliferating hematologic malignancies or advanced solid tumor following cytotoxic chemotherapy or therapeutic interventions. TLS is especially rare in patients with hepatocellular carcinoma (HCC). Therefore, we present a case of a female patient with newly diagnosed advanced HCC who developed TLS and hepatic failure after receiving combination therapy of nivolumab and sorafenib. To our knowledge, this is the first case of TLS in a patient with advanced HCC owing to combination therapy of nivolumab and sorafenib. We also reviewed the literature and summarized the characteristics of TLS in patients with advanced HCC receiving various therapeutic interventions. The overall mortality rate was 63% and regarding the management, transarterial chemoembolization (TACE) was the most common etiology. TACE-related TLS developed more rapidly than sorafenib-related TLS. Furthermore, the efficacy and safety of combination therapy of nivolumab and sorafenib should be further evaluated, and TLS should still be a concern, especially in patients with large tumor burden.https://www.karger.com/Article/FullText/508583tumor lysis syndromenivolumabsorafenibadvanced hepatocellular carcinoma |
| spellingShingle | Tsai-Hung Yen Chung-Hsin Chang Sz-Iuan Shiu Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma Case Reports in Gastroenterology tumor lysis syndrome nivolumab sorafenib advanced hepatocellular carcinoma |
| title | Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma |
| title_full | Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma |
| title_fullStr | Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma |
| title_full_unstemmed | Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma |
| title_short | Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma |
| title_sort | tumor lysis syndrome after combination therapy of nivolumab and sorafenib in a woman with advanced hepatocellular carcinoma |
| topic | tumor lysis syndrome nivolumab sorafenib advanced hepatocellular carcinoma |
| url | https://www.karger.com/Article/FullText/508583 |
| work_keys_str_mv | AT tsaihungyen tumorlysissyndromeaftercombinationtherapyofnivolumabandsorafenibinawomanwithadvancedhepatocellularcarcinoma AT chunghsinchang tumorlysissyndromeaftercombinationtherapyofnivolumabandsorafenibinawomanwithadvancedhepatocellularcarcinoma AT sziuanshiu tumorlysissyndromeaftercombinationtherapyofnivolumabandsorafenibinawomanwithadvancedhepatocellularcarcinoma |